CALA - Calithera Biosciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.27
+0.14 (+2.28%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close6.13
Open6.15
Bid5.92 x 1000
Ask6.40 x 800
Day's range6.00 - 6.28
52-week range2.45 - 8.18
Volume716,491
Avg. volume875,655
Market cap441.683M
Beta (5Y monthly)2.35
PE ratio (TTM)N/A
EPS (TTM)-1.69
Earnings date07 May 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.80
  • Has Calithera Biosciences (CALA) Outpaced Other Medical Stocks This Year?
    Zacks

    Has Calithera Biosciences (CALA) Outpaced Other Medical Stocks This Year?

    Is (CALA) Outperforming Other Medical Stocks This Year?

  • Is Calithera Biosciences (CALA) Stock a Solid Choice Right Now?
    Zacks

    Is Calithera Biosciences (CALA) Stock a Solid Choice Right Now?

    Calithera Biosciences (CALA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • What Makes Calithera (CALA) a New Buy Stock
    Zacks

    What Makes Calithera (CALA) a New Buy Stock

    Calithera (CALA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Calithera Biosciences Inc (CALA) Q1 2020 Earnings Call Transcript
    Motley Fool

    Calithera Biosciences Inc (CALA) Q1 2020 Earnings Call Transcript

    Joining me today are Susan Molyneaux, our Founder, President and CEO; Keith Orford, Chief Medical Officer; and Stephanie Wong, Senior Vice President of Finance. Before we begin, I would like to remind you that today's discussion will include statements about our forward -- future expectations, plans and prospects that constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995.

  • GlobeNewswire

    Calithera Biosciences Reports First Quarter 2020 Financial Results and Recent Highlights

    --Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on May 7, 2020-- SOUTH SAN FRANCISCO, Calif., May 07, 2020 -- Calithera.

  • GlobeNewswire

    Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    One-fourth of the option vests on April 6, 2021, and the balance of the option vests in a series of thirty-six successive equal monthly installments thereafter and was granted pursuant to the Calithera Biosciences, Inc. 2018 Inducement Plan, or Inducement Plan, which was approved by Calithera’s board of directors in January 2018 in accordance with Nasdaq Listing Rule 5653(c)(4). The stock option also has a ten year term and is subject to the terms and conditions of the Inducement Plan and the stock option agreement pursuant to which the option was granted.

  • GlobeNewswire

    Calithera Biosciences to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020

    Company management will host a conference call on Thursday, May 7, 2020 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients.

  • GlobeNewswire

    Calithera Biosciences Announces Telaglenastat KEAPSAKE Trial in Progress Abstract Accepted for Presentation at ASCO20 Virtual Annual Meeting

    SOUTH SAN FRANCISCO, Calif., April 30, 2020 -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel.

  • GlobeNewswire

    Calithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares

    Gross proceeds from the offering at a public offering price of $6.25 per share, before underwriting discounts and commissions and offering expenses, were approximately $36 million. A shelf registration statement relating to the offered shares of common stock was filed with the Securities and Exchange Commission (SEC), and was declared effective. Copies of the prospectus related to the offering may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York, 11717 or by telephone at (800) 831-9146.

  • GlobeNewswire

    Calithera Biosciences, Inc. Prices Public Offering of 5,000,000 shares of Common Stock

    All of the shares of common stock are being offered by Calithera. In addition, Calithera has granted the underwriter a 30-day option to purchase up to 750,000 of additional shares of common stock at the public offering price. A shelf registration statement relating to the offered shares of common stock was filed with the Securities and Exchange Commission (SEC), and was declared effective.

  • GlobeNewswire

    Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock

    All of the shares of common stock are being offered by Calithera. Citigroup is acting as sole book-running manager for the offering. In connection with this offering, Calithera expects to grant Citigroup a 30-day option to purchase an additional 15% of the shares of common stock offered in the public offering.

  • Calithera (CALA) Soars: Stock Adds 9.4% in Session
    Zacks

    Calithera (CALA) Soars: Stock Adds 9.4% in Session

    Calithera (CALA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

  • GlobeNewswire

    Calithera Biosciences Provides Update on Business Operations

    Randomized CANTATA trial of telaglenastat and cabozantinib in advanced renal cell carcinoma. The CANTATA trial was fully enrolled in October 2019 and Calithera advised at that time that the company planned to report top-line efficacy and safety data from the trial in the second half of 2020, and more recently guided towards late third quarter or fourth quarter of 2020.

  • GlobeNewswire

    Calithera Biosciences Reports Fourth Quarter 2019 Financial Results and Recent Highlights

    SOUTH SAN FRANCISCO, Calif., March 11, 2020 -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel.

  • GlobeNewswire

    Calithera Biosciences to Report Fourth Quarter 2019 Financial Results on Wednesday, March 11, 2020

    Calithera Biosciences, Inc. (CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company’s fourth quarter 2019 financial results will be released on Wednesday, March 11, 2020. Company management will host a conference call on Wednesday, March 11, 2020 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com.

  • GlobeNewswire

    Calithera to Participate in the 9th Annual SVB Leerink Global Healthcare Conference

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the SVB Leerink Global Healthcare Conference at 10:30 a.m. ET on Thursday, February 27, 2020, in New York City. Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients.

  • GlobeNewswire

    Calithera Biosciences Provides Overview of 2020 Corporate Milestones and Financial Guidance

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, provided today an overview of select expected fourth quarter 2019 financial results, initial 2020 financial guidance and upcoming corporate milestones. "We anticipate that 2020 will be an exciting year for Calithera, building on the substantial progress we made in 2019 and the potential for several significant clinical and regulatory milestones," said Susan Molineaux, PhD, president and chief executive officer of Calithera. Announce topline data from randomized CANTATA trial of telaglenastat with cabozantinib in advanced renal cell carcinoma (RCC).

  • GlobeNewswire

    Data from Investigator-Sponsored Phase 2 Study of Calithera’s Telaglenastat with Azacitidine in Myelodysplastic Syndrome to be Presented at ASH Annual Meeting 2019

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that preliminary safety and efficacy data from an investigator-sponsored trial evaluating telaglenastat (CB-839) in combination with azacitidine will be presented in an oral session at the American Society of Hematology (ASH) Annual Meeting 2019 taking place December 7-10, in Orlando, Florida.

  • GlobeNewswire

    Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the compensation committee of the company’s board of directors granted four new employees non-qualified stock options to purchase an aggregate of 52,500 shares of Calithera’s common stock, at a per share exercise price of $4.92, the closing trading price on November 29, 2019. The stock options vest monthly over four years and were granted pursuant to the Calithera Biosciences, Inc. 2018 Inducement Plan, or Inducement Plan, which was approved by Calithera’s board of directors in January 2018 in accordance with Nasdaq Listing Rule 5653(c)(4).

  • GlobeNewswire

    Calithera Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights

    SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel.

  • GlobeNewswire

    Calithera to Present Preclinical Data from IL4I1 and CD73 Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that new data from its research and development portfolio have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting taking place November 6-10, 2019, in National Harbor, Maryland. “We look forward to sharing the first data on IL4I1, which is an investigational first-in-class small molecule immune-oncology program, as well as new data from the development program for our novel CD73 inhibitor CB-708,” said Susan Molineaux, PhD, president and chief executive officer of Calithera.